Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

Oxymatrine regulates SPHKS/S1P signaling pathway in diabetic retinopathy: an observational clinical cohort study.

  • 2026-04-24
  • Scientific reports 16(1)
    • Jin Xu
    • Yan Li
    • Ge-Yao Qi
    • Juan Feng
    • Fei Wang

Study Design

Type
Observational
Sample size
n = 84
Population
84 DR cases (41 OMT group, 43 non-OMT group) plus 20 non-DR blank controls
Methods
Observation cohort study; 84 DR cases assigned to OMT or non-OMT group; peripheral blood levels of S1P, VEGF, SPHK1, SPHK2 measured and temporal changes compared
Funding
Unclear
  • Rigorous Journal

Background

The SPHKS/S1P pathway has a complex yet close association with the progression of diabetic retinopathy (DR). Oxymatrine (OMT), is believed to potentially regulate this pathway; however, systematic clinical evidence remains insufficient.

Methods

A total of 84 DR cases was finally included in the observation cohort, among which 41 cases were assigned to the OMT group and 43 cases to the non-OMT group. Additionally, 20 non-DR cases were included as blank controls. The levels of 4 target proteins, including S1P, VEGF, SPHK1, and SPHK2, were detected in the peripheral blood of cases in each group. The temporal changes in these protein levels were compared between the OMT group and the non-OMT group. Furthermore, the progression of DR between the two groups was statistically analyzed before and after treatment.

Results

Compared with non-DR cases, the levels of 4 target proteins of DR cases were significantly increased. No statistically significant differences in the levels of these proteins were observed between the OMT group and the non-OMT group before treatment; the temporal change trends in the expression levels of these proteins in the OMT group were significantly lower than those in the non-OMT group after treatment. However, no statistically significant differences were found between the OMT group and the non-OMT group in terms of DR progression.

Conclusion

OMT could inhibit the activity of the SPHKS/S1P pathway and downregulate the expression of key proteins; however, the clinical efficacy of OMT in relieving the progression of DR remained unclear in this study.

Research Insights

  • Sophora→Reduced Diabetic Retinopathy Progression

    no statistically significant differences were found between the OMT group and the non-OMT group in terms of DR progression

    Effect
    Neutral
    Effect size
    Small
  • Sophora→Reduced Sphingosine Kinase 1 Level

    the temporal change trends in the expression levels of these proteins in the OMT group were significantly lower than those in the non-OMT group after treatment

    Effect
    Beneficial
    Effect size
    Small
  • Sophora→Reduced Sphingosine Kinase 2 Level

    the temporal change trends in the expression levels of these proteins in the OMT group were significantly lower than those in the non-OMT group after treatment

    Effect
    Beneficial
    Effect size
    Small
  • Sophora→Reduced Sphingosine-1-phosphate Level

    the temporal change trends in the expression levels of these proteins in the OMT group were significantly lower than those in the non-OMT group after treatment

    Effect
    Beneficial
    Effect size
    Small
  • Sophora→Reduced Vascular Endothelial Growth Factor Level

    the temporal change trends in the expression levels of these proteins in the OMT group were significantly lower than those in the non-OMT group after treatment

    Effect
    Beneficial
    Effect size
    Small
Back to top